ANTH News
Archived Headlines
- Anthera Pharmaceuticals cuts deal size 02/24/10
- 1 IPO planned for the week of Feb 22 02/21/10
- Tuesday sees six IPO filings, highest same-day number in over two years 02/18/10
- Anthera Pharmaceuticals announces IPO terms 02/03/10
- Anti-inflammatory drug developer Anthera Pharmaceuticals files for an IPO 09/16/09
Anthera Pharma quiet period ends April 9
Anthera Pharmaceuticals, a biotech that is developing anti-inflammatory therapies for acute coronary syndrome and lupus, will see its quiet period end this Friday, April 9th. On February 28th, the company raised $42 million by offering 6 million shares at $7,...read more
Anthera Pharmaceuticals prices IPO at $7, 50 percent below the proposed range
Anthera Pharmaceuticals, a biotech developing a Phase 3 anti-inflammatory treatment for acute coronary syndrome, raised $42 million by offering 6 million shares at $7 per share after originally filing to raise almost $65 million by offering 4.6 million shares at...read more
1 IPO planned for the week of Mar 1
Anthera Pharmaceuticals, which is developing anti-inflammatory therapies for acute coronary syndrome and lupus, plans to raise $42 million by offering 6 million shares at a price of $7 per share, according to a post-effective amendment filed on Friday. Venture...read more
Anthera Pharmaceuticals to raise $42 million, cuts original deal size by 35 percent
According to a post-effective amendment filed earlier today, biotech Anthera Pharmaceuticals now plans to raise $42 million by offering 6 million shares (6.9 million with the overallotment) at $7 per share instead of the previously expected 4.6 million shares at...read more